strategicmind

$REPL $CADL All eyes on REPL this week with PDUFA Tuesday, July 22. Viral immunotherapies have come a long way and think with the FDA nod, its further validation the science is top tier. Also given the similarities between CADL and REPL MOA using HSV, should only benefit CADL.

$CADL Here is a nice stat. % of biotech companies with stat sig phase 3 trial - hit primary & secondary endpoints done under SPA go on to get FDA approval? @paulpetertak CEO says it’s 92% in last video with @ideapharma. Looks spot on!!!!!

$CADL NEW market Data out from CADL. I know they have been doing market research and the TAM of prostate has been updated!!!! They now see it as 11B + opportunity. The range is 10-16B in US ALONE.

$CADL Excellent comments here from CADL CSO Dr. Francesca Barone of CADL in terms of Rolling BLA and CAN-3110 excitement later this year!!! #bofa #bankofamerica #biotech #FDA #cancer #investing She did a great job for this short presentation.

$CADL Dr. Paul Peter Tak’s comments, Couldn’t have said it any better! I think this is a table pounding buy opportunity.

$CADL great news and potentially first of many things to come to help biotech. @paulpetertak @ideapharma

$CADL very interesting in terms of rolling BLA submission. New admin talking about making this actually useful to help expedite path to approval in regards to CMC & trial data etc. @paulpetertak @ideapharma

$CADL sounds a lot like @DrMakaryFDA is referring to CAN-3110’s incredible result on specific patients with recurrent high- grade glioma. @paulpetertak . He even mentioned he heard from his “past colleagues” few sit on the CADL board/ research advisory board from John Hopkins.

$CADL Carl June- Tuning into the cell & gene therapy discussions with FDA. It’s very enlightening to hear the FDA being so open to hearing from the best in the field. So many changes coming!!! ir.candeltx.com/news-releases/… youtube.com/live/0qDhRtnHX…

They will be drooling over $CADL assets!! @paulpetertak @ideapharma